Investigating the antiparasitic potential of the marine sesquiterpene avarone, its reduced form avarol, and the novel semisynthetic thiazinoquinone analogue thiazoavarone by IMPERATORE, CONCETTA et al.
marine drugs 
Article
Investigating the Antiparasitic Potential of the
Marine Sesquiterpene Avarone, Its Reduced Form
Avarol, and the Novel Semisynthetic
Thiazinoquinone Analogue Thiazoavarone
Concetta Imperatore 1,2,† , Roberto Gimmelli 3,†, Marco Persico 1,2,†, Marcello Casertano 1,2 ,
Alessandra Guidi 3, Fulvio Saccoccia 3, Giovina Ruberti 3 , Paolo Luciano 1, Anna Aiello 1,2,
Silvia Parapini 4 , Sibel Avunduk 5, Nicoletta Basilico 6 , Caterina Fattorusso 1,2,* and
Marialuisa Menna 1,2,*
1 The NeaNat Group, Department of Pharmacy, University of Naples “Federico II”, Via D. Montesano 49,
80131 Napoli, Italy; cimperat@unina.it (C.I.); marco.persico@unina.it (M.P.);
marcello.casertano@unina.it (M.C.); pluciano@unina.it (P.L.); aiello@unina.it (A.A.)
2 Italian Malaria Network, Centro Interuniversitario di Ricerche Sulla Malaria (CIRM), Department of
Pharmacy, University of Naples “Federico II”, Via D. Montesano 49, 80131 Napoli, Italy
3 Institute of Biochemistry and Cell Biology, National Research Council, Campus A. Buzzati-Traverso, Via E.
Ramarini, 32, 00015 Monterotondo (Roma), Italy; roberto.gimmelli@ibbc.cnr.it (R.G.);
alessandra.guidi@ibbc.cnr.it (A.G.); fulvio.saccoccia@ibbc.cnr.it (F.S.); giovina.ruberti@cnr.it (G.R.)
4 Dipartimento di Scienze Biomediche per la Salute, Università di Milano, Via Pascal 36, 20133 Milan, Italy;
silvia.parapini@unimi.it
5 Department Vocational School of Medicinal Health Services, Mugla University, 48187 Mugla, Turkey;
sibelavunduk@mu.edu.tr
6 Dipartimento di Scienze Biomediche, Chirurgiche e Odontoiatriche, Università di Milano, Via Pascal 36,
20133 Milan, Italy; nicoletta.basilico@unimi.it
* Correspondence: caterina.fattorusso@unina.it (C.F.); mlmenna@unina.it (M.M.);
Tel.: +39081678544 (C.F.); +39081678518 (M.M.)
† These authors equally contributed.
Received: 9 January 2020; Accepted: 11 February 2020; Published: 14 February 2020


Abstract: The chemical analysis of the spongeDysidea avara afforded the known sesquiterpene quinone
avarone, along with its reduced form avarol. To further explore the role of the thiazinoquinone
scaffold as an antiplasmodial, antileishmanial and antischistosomal agent, we converted the quinone
avarone into the thiazinoquinone derivative thiazoavarone. The semisynthetic compound, as well as
the natural metabolites avarone and avarol, were pharmacologically investigated in order to assess
their antiparasitic properties against sexual and asexual stages of Plasmodium falciparum, larval and
adult developmental stages of Schistosoma mansoni (eggs included), and also against promastigotes
and amastigotes of Leishmania infantum and Leishmania tropica. Furthermore, in depth computational
studies including density functional theory (DFT) calculations were performed. A toxic semiquinone
radical species which can be produced starting both from quinone- and hydroquinone-based
compounds could mediate the anti-parasitic effects of the tested compounds.
Keywords: Dysidea avara; avarone/avarol; redox-active compounds; quinones and hydroquinones;
dioxothiazinoquinone; Schistosoma mansoni; Plasmodium falciparum; Leishmania spp.; 3D-SAR analysis;
DFT studies
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1. Introduction
Malaria and neglected tropical diseases (NTDs), a group of parasitic, bacterial, and viral infectious
diseases (i.e., Schistosoma spp., Leishmania spp.), still have high morbidity and/or mortality rates
worldwide. They affect more than one billion people and cause chronic illness, physical disability
and/or deaths, especially in children and women of childbearing age, mostly in developing countries
where they represent a serious hurdle to social and economic growth as well as a health problem [1,2].
Parasites belonging to different species can affect humans and animals concurrently, a phenomenon
referred to as multiparasitism, which poses additional diagnostic and therapeutic challenges [3].
The therapeutic strategies for malaria and NTDs are very limited; drug-resistance phenomena, toxicity
profiles and drug administration procedures of the few available chemical entities are still challenging.
In this view, a research aimed to discover new chemicals active against several parasites is crucial and
the marine environment may be an important resource [4,5]. In order to cope with all the reported
drawbacks and to limit the costs of the development of brand-new pharmaceutical strategies, several
effective antimalarial drugs should be considered for the treatment of other underfunded parasitic
diseases. For example, artemisinin and its derivatives, a potent class of antimalarial agents, have been
proved to be beneficial for other infectious diseases such as schistosomiasis and leishmaniasis [6].
Furthermore, histone deacetylases (HDAC) inhibitors have been shown to have activity both against
some Plasmodium species as well as Leishmania and Schistosoma parasites [7]. Importantly, the blood
parasites, Plasmodium and Schistosoma, both feeding on human hemoglobin, can detoxify the free heme
groups through the synthesis of insoluble hemozoin pigments [8]. The interference with hemozoin
formation featured an important antischistosomal mechanism of action showed by the antimalarial
quinine and quinidine [9].
In the frame of our research for new anti-parasitic chemical entities, we recently identified the
thiazinoquinone scaffold as a novel chemotype active against bothPlasmodium falciparum andSchistosoma
mansoni [10–14]. We developed this scaffold by creating of a chemical library of thiazinoquinone
derivatives designed on the model of aplidinones, natural products isolated from a marine invertebrate
(Figure 1). Many compounds exhibited in vitro antiplasmodial activities against the D10 and W2 strains
of P. falciparum [11,13] with IC50 in the low micromolar range. Through an integrated experimental
(cyclic voltammetry) and theoretical approach, we demonstrated that the antiplasmodial and anticancer
activity of a series of thiazinoquinone compounds was not related to their two electrons redox
potential [11,12]. In particular, the antiplasmodial activity was found to depend on the ability of the
compound to generate a semiquinone radical species able to form a stable adduct with heme [11].
This was later supported by the design and synthesis of other sets of new thiazinoquinone derivatives,
indicating that the activity was related to the ability to form a specific semiquinone radical, and to
the ability of this latter to transfer the radical by and hydrogen-radical shift to the R substituent [13].
In addition, several important SARs were obtained. First, the thiazinoquinone moiety was ascertained
to be necessary for the antiplasmodial activity, since the corresponding quinone derivatives (e.g.,
derivatives lacking the 1,1-dioxothiazine moiety) were inactive. Second, the regiochemistry of the
heterocyclic ring with respect to the substituents (a methoxyl group and an alkyl chain) on the quinone
ring was revealed as crucial for the activity. Third, the nature and shape of the R′ substituent were able
to affect compound potency and selectivity.
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Figure 1. Structures of aplidinones A, B and of thiazinoquinone derivatives. 
Successively, we selected both some of the developed methoxy thiazinoquinones, and some ad 
hoc synthesized new derivatives with the aim of investigating the antischistosomal properties of this 
chemical scaffold. Compounds were thus tested against larval stage, adult worm couples and eggs 
of the platyhelminth S. mansoni [14]. Many of the tested molecules resulted active and, interestingly, 
as observed for the antiplasmodial activity, the effects against S. mansoni strongly depended on the 
regiochemistry of the heterocyclic ring, and from the nature and/or steric hindrance of the R’ 
substituent. Computational studies indicated that semiquinone radical species could be involved also 
in the mode of action against S. mansoni impairing the redox equilibrium within the parasite. 
Importantly, the R’ properties can affect both the pharmacodynamics and pharmacokinetics of the 
compounds [14]. 
In the course of a systematic chemical study of the macroflora and macrofauna of the coastal 
area of Turkey in the İzmir Bay (Aegean Sea), as a part of our ongoing search for bioactive marine-
derived metabolites as leads for drug discovery [15–20], we isolated from the sponge Dysidea avara 
(Schmidt, 1862) the known sesquiterpene quinone avarone (1), along with its reduced form avarol (3, 
Figure 2) [21–23]. A wide range of pharmacological properties have been reported for the redox 
couple avarone (1) and avarol (3) including anti-tumor [24–26], anti-inflammatory [27–29], anti-
mutagenic [30], anti-bacterial [31,32], anti-viral [33,34], anti-oxidant [23,35], anti-platelet [28], anti-
psoriatic [36] and anti-biofouling [37,38] activities. Pharmacological studies on synthetic and 
semisynthetic derivatives of avarone have been previously reported, too [23,39–41]. Based on the 
above described extensive exploration of the thiazinoquinone scaffold as antiplasmodial and 
antischistosomal agent [11,13,14], we used the quinone avarone (1) as chemical starting point to 
obtain the semisynthetic thiazinoquinone derivative, thiazoavarone (2, Figure 2). Compound 2, as 
well as the natural metabolites 1 and 3, were investigated in order to evaluate their in vitro activity 
against: (i) asexual stages of D10 and W2 strains and stage V gametocytes of P. falciparum, (ii) egg 
production, larval and adult stages of S. mansoni, (iii) promastigote and amastigote stages of 
Leishmania infantum and Leishmania tropica. Computational studies, including density functional 
theory (DFT) calculations, were performed in order to analyze the conformational and redox 
properties of the two natural metabolites (1 and 3), as well as those of the novel semisynthetic 
analogue 2.  
The obtained results shed light on the putative mechanism of action of the 
quinone/hydroquinone/thiazinoquinone compounds corroborating the hypothesis that their 
antiparasitic activity is related to the formation of a toxic semiquinone radical species. Noteworthy, 
thiazoavarone 2 resulted the most potent antimalarial thiazinoquinone developed by us, highlighting 
the important role for the activity played by the substituent of the 1,1-dioxo-1,4-thiazine ring.  
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Successively, we selected both some of the developed methoxy thiazinoquinones, and some ad
hoc synthesized new derivatives with the aim of investigating the antischistosomal properties of this
chemical scaffold. Compounds were thus tested against larval stage, adult worm couples and eggs
of the platyhelminth S. mansoni [14]. Many of the tested molecules resulted active and, interestingly,
as observed for the antiplasmodial activity, the effects against S. mansoni strongly depended on the
regiochemistry of the heterocyclic ring, and from the nature and/or steric hindrance of the R′ substituent.
Computational studies indicated that semiquinone radical species could be involved also in the mode
of action against S. mansoni impairing the redox equilibrium within the parasite. Importantly, the R′
properties can affect both the pharmacodynamics and pharmacokinetics of the compounds [14].
In the course of a systematic chemical study of the macroflora and macrofauna of the coastal
area of Turkey in the I˙zmir Bay (Aegean Sea), as a part of our ongoing search for bioactive
marine-derived metabolites as leads for drug discovery [15–20], we isolated from the sponge Dysidea
avara (Schmidt, 1862) the known sesquiterpene quinone avarone (1), along with its reduced form
avarol (3, Figure 2) [21–23]. A wide range of pharmacological properties have been reported for
the redox couple avarone (1) and avarol (3) including anti-tumor [24–26], anti-inflammatory [27–29],
anti-mutagenic [30], anti-bacterial [31,32], anti-viral [33,34], anti-oxidant [23,35], anti-platelet [28],
anti-psoriatic [36] and anti-biofouling [37,38] activities. Pharmacological studies on synthetic and
semisynthetic derivatives of avarone have been previously reported, too [23,39–41]. Based on the above
described extensive exploration of the thiazinoquinone scaffold as antiplasmodial and antischistosomal
agent [11,13,14], we used the quinone avarone (1) as chemical starting point to obtain the semisynthetic
thiazinoquinone derivative, thiazoavarone (2, Figure 2). Compound 2, as well as the natural metabolites
1 and 3, were investigated in order to evaluate their in vitro activity against: (i) asexual stages of D10
and W2 strains and stage V gametocytes of P. falciparum, (ii) egg production, larval and adult stages
of S. mansoni, (iii) promastigote and amastigote stages of Leishmania infantum and Leishmania tropica.
Computational studies, including density functional theory (DFT) calculations, were performed in
order to analyze the conformational and redox properties of the two natural metabolites (1 and 3), as
well as those of the novel semisynthetic analogue 2.
The obtained results shed light on the putative mechanism of action of the
quinone/hydroquinone/thiazinoquinone compounds corroborating the hypothesis that their
antiparasitic activity is related to the formation of a toxic semiquinone radical species. Noteworthy,
thiazoavarone 2 resulted the most potent antimalarial thiazinoquinone developed by us, highlighting
the important role for the activity played by the substituent of the 1,1-dioxo-1,4-thiazine ring.
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Figure 2. Structure of avarone (1), the semisynthetic thiazoavarone (2) and avarol (3). 
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Avarone (1) and avarol (3) were isolated from the sponge D. avara and purified according to the 
previously described procedures [21–23]. They were easily identified by comparison of their 
spectroscopic properties (1H and 13C NMR, HRESI-MS) with those reported in literature [21–23]. 
Thiazoavarone (2) was prepared as reported in Scheme 1. A portion of avarone was dissolved in 
a solution of CH3CN/EtOH (1:1) and then hypotaurine and a catalytic amount of salcomine in portion 
were added. The mixture was stirred for 48 h at room temperature and then was extracted with 
diethyl ether. The crude material was purified by HPLC on a reverse phase column (Luna 3 µm, 150 
× 3.00 mm) (MeOH/H2O 75:25 v/v%) to afford the pure compound 2. The nucleophilic addition 
reaction is regioselective in unsymmetrical quinones but generally leads to the formation of both 
regioisomers one of which is obtained in large excess with respect to the other. In the case of avarone, 
a single isomeric product, thiazoavarone 2, has formed, as determined by MS and NMR spectroscopy; 
this could be reasonably due to the high steric hindrance of the heavy sesquiterpene moiety.  
 
 
 
 
 
 
 
 
Scheme 1. Coupling of avarone (1) with hypotaurine via nucleophilic addition reaction. 
Compound 2, obtained as yellow powder, [α]D25 = +19.2 (c 0.004, MeOH), had a molecular 
formula of C23H31NO4S as determined by the HRESI MS ion at m/z C23H31NO4SNa [M + Na]+ 440.1865 
(calculated value: 440.1866). Molecular formula obtained from MS and a first survey of the 1D NMR 
spectra of 2 (CDCl3) and the comparison with those of the known avarone 1 quickly allowed us to 
hypothesize that the condensation reaction with hypotaurine has occurred. 1H and 13C NMR data of 
2 indicated the same decalin ring system of 1, and the only difference between the two compounds 
is in the quinonic portion. Indeed, 1H NMR spectrum of 2 lacked the signals at δH 6.51 and 6.71, 
whereas contained a quite deshielded methylene signals (δH3.30 and 4.05), resonating as two 
multiplets and each integrating for two protons. Likewise, the 13C spectrum of 2 contained two 
additional methilene carbon resonances at δC 39.8 and at δC 48.8 attributable to a nitrogen and 
sulfoxide-bearing carbons, respectively. The key HMBC cross-peaks (Figure 3) from H-3’ to C-2’ (δC 
48.8), C-4a’ (δC 143.2), and from H-2’ to C-3’ (δC 39.8), C-8a’ (δC 111.6), from H-6’ to C-4a’ (δC 143.2), 
and from H-15a and H-15b’ to C-8’ (δC 177.1) indicated the regiochemistry of 2. It should be noted 
that only one of possible regioisomer has been obtained.  
Figure 2. Structure of avarone (1), the semisynthetic thiazoavarone (2) and avarol (3).
2. Re ults and Di cussion
2.1. Chemistry
Avarone (1) and avarol (3) were isolated from the sponge D. avara and purifie according to
the previously described procedures [21–23]. They were easily identified by comparison of their
spectroscopic properties (1H and 13C NM , HRESI-MS) with those reported in literature [21–23].
Thiazoavarone (2) was prepared as reported in Scheme 1. A portion of avarone was dissolved
in a solution of CH3CN/EtOH (1:1) and then hypotaurine and a catalytic amount of salcomine in
portion were added. The mixture was stirred for 48 h at room temperature and then was extracted
with diethyl ether. The crude material was purified by HPLC on a reverse phase column (Luna 3 µm,
150 × 3.00 mm) (Me H/H2O 75:25 v/v%) to afford the pure compound 2. The nucleophilic addition
reaction is regioselective i unsymmetrical quinones but generally leads to the formation of both
regioisomers one of which is obtained in large excess with respect to the other. In the case of avarone, a
single isomeric product, thiazoavarone 2, has formed, as determined by MS and NMR spectroscopy;
this could be reasonably due to the high steric hindrance of the heavy sesquiterpene moiety.
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Scheme 1. Coupling of avarone (1) with hypotaurine via nucleophilic addition reaction.
Compound 2, obtained as yellow powder, [α]D25 = +19.2 (c 0.004, MeOH), had a molecular
formula of C23H31NO4S as determined by the HRESI MS ion at m/z C23H31NO4SNa [M + Na]+ 440.1865
(calculated value: 440.1866). Molecular formula obtained from MS and a first survey of the 1D NMR
spectra of 2 (CDCl3) and the comparison with those of the known avarone 1 quickly allowed us to
hypothesize that the condensation reaction ith hypotaurine has occurred. 1H and 13C NMR data of 2
indicated the same decalin ring system of 1, and the only difference between the two compounds is in
the quinonic portion. Indeed, 1H NMR spectrum of 2 lacked the signals at δH 6.51 and 6.71, whereas
contained a quite deshielded methylene signals (δH3.30 and 4.05), resonating as two multiplets and
each integrating for two protons. Likewise, the 13C spectrum of 2 contained two additional methilene
carbon resonances at δC 39.8 and at δC 48.8 attributable to a nitrogen and sulfoxide-bearing carbons,
respectively. The key HMBC cross-peaks (Figure 3) from H-3′ to C-2′ (δC 48.8), C-4a′ (δC 143.2), and
from H-2′ to C-3′ (δC 39.8), C-8a′ (δC 111.6), from -6′ to C-4a′ (δC 143.2), and from H-15a and H-15b′
to C-8′ (δC 177.1) indicated the regiochemistry of 2. It should be noted that only one of possible
regioiso er has been obtained.
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thiazinoquinone scaffold for development of new antimalarial hits. Interestingly, both natural 
compounds 1 and 3 also exhibited a remarkable effect against sensitive and resistant P. falciparum 
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gametocytes with respect to the parasite asexual stage; this finding is not unexpected since most of 
the current antimalarial drugs have no effect on the late stage of gametocytes. Avarol (3) resulted the 
Figure 3. Key 1H-13C HMBC correlations of thiazoavarone (2).
Chemical shifts and coupling patterns of the all signals of 2 were assigned by aid of COSY, HSQC,
and HMBC experiments (Table 1). Anyway, a purity higher than 99.8% has been determined by HPLC
for compounds 1–3.
Table 1. 1H (700 MHz) and 13C (125 MHz) NMR data of thiazoavarone (2) in CDCl3.
Pos. δC δH, mult. (J in Hz) Pos. δC δH, mult. (J in Hz)
1′ - - 4 143.7 -
2′ 48.8 3.30, m 5 38.3 -
3′ 39.8 4.05, m 6 35.8 1.03 a, 1.64 a
4′ - 6.41, br s 7 27.3 1.38 a
4a′ 143.2 - 8 37.1 1.25 a
5′ 179.3 - 9 43.7 -
6′ 131.8 6.50, s 10 47.5 1.03 a
7′ 152.8 - 11 17.9 1.53, s
8′ 177.1 - 12 20.0 0.99, s
8a′ 111.6 - 13 16.7 0.96, d, (6.2)
1 19.3 1.50
a, 1.85, dd, (6.7,
13.2) 14 17.7 0.85, s
2 26.3 1.93 a, 2.04 a 15a
35.6
2.50, d, (13.1)
3 120.9 5.2, br s 15b 2.70, d, (13.1)
a Overlapped by other signals.
2.2. In Vitro Activity on P. falciparum and Cytotoxicity
Avarone (1) and the semisynthetic 1,1-dioxo-1,4-thiazine analogue (2), as well as hydroquinone
avarol (3) were tested for their in vitro antiplasmodial activity against asexual and sexual (gametocytes
stage V) stages of P. falciparum (Table 2). A chloroquine-sensitive (CQ-S) D10 and a chloroquine-resistant
(CQ-R) W2 strains were used to determine the IC50 against asexual stage of parasites. The most
potent compound was thiazoavarone (2) with an IC50 value in the nanomolar range, higher than those
exhibited by the previously identified synthetic lead [13]. The high potency of the thiazinoquinone
2, specifically on the chloroquine-resistant strain W2 and compared with avarone (1), lacking the
heterocyclic moiety, confirmed once again the high potential of the thiazinoquinone scaffold for
development of new antimalarial hits. Interestingly, both natural compounds 1 and 3 also exhibited
a remarkable effect against sensitive and resistant P. falciparum strains, showing no cross-resistance
with chloroquine (see Table 2). In particular, the reduced hydroquinone form (avarol, 3) resulted
significantly more active than the oxidized quinone form (avarone, 1).
The evaluation of the effects of compounds 1–3 on Pf gametocytes stage V, the sexual stage
circulating in the bloodstream, was performed in order to evaluate their transmission blocking
potential. As evidenced in Table 2, all the three compounds resulted less active against the gametocytes
with respect to the parasite asexual stage; this finding is not unexpected since most of the current
antimalarial drugs have no effect on the late stage of gametocytes. Avarol (3) resulted the most potent
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in the series against Pf gametocytes stage V with an IC50 = 9.30 µM, comparable to that of OZ27, a
drug in clinical development (IC50 = 6.4 µM) [42].
Table 2. In vitro antimalarial activity against asexual P. falciparum parasites from D10 (CQ-sensitive)
and W2 (CQ-resistant) strains a and against stage V P. falciparum gametocytes from a 3D7 transgenic line.
Compounds D10 (µM) b W2 (µM) b
Pf Gametocytes Stage V
3D7elo1-pfs16-CBG99 IC50 (µM) b
Avarone (1) 2.74 ± 0.51 2.09 ± 0.52 15.53 ± 5.26
Thiazoavarone (2) 0.38 ± 0.15 0.21 ± 0.03 15.01 ± 3.19
Avarol (3) 0.96 ± 0.24 1.10 ± 0.15 9.30 ± 1.90
Methylene blue - - 0.155 ± 0.05
a Chloroquine (CQ) has been used as positive control (D10 IC50 = 0.04 ± 0.01; W2 IC50 = 0.54 ± 0.28). b The results
are the mean ± SD of IC50 of three independent experiments performed in duplicate.
Finally, we tested compounds 1–3 for their cytotoxic effects against two different human cell
lines, microvascular endothelial (HMEC-1) and acute monocytic leukemia (THP-1) cells differentiated
into macrophages; for each compound, we evaluated the selectivity index (SI, Table 2), namely the
ratio between the IC50 on the human cells HMEC and that on the parasite strains (see Table 3).
Thiazoavarone (2) exhibited a high toxicity against both mammalian cell lines, with IC50 in the low
micromolar concentration range and, consequently, a very low SI. Avarone and avarol (1 and 3) were
lowly and moderately cytotoxic, respectively (Table 3) but the hydroquinone 3 exhibited a better SI.
Table 3. IC50 against HMEC-1 (human microvascular endothelial cells) and THP-1 (human acute
monocytic leukemia cells) and Selectivity Index (SI) of the compounds 1–3.
Compounds HMEC-1 IC50
(µM) a,b
THP-1 IC50 (µM)
a,c
SI d
D10 W2
Avarone (1) 62.19 ± 1.98 >100 22.7 29.8
Thiazoavarone (2) 3.31 ± 1.53 7.41 8.7 15.8
Avarol (3) 36.85 ± 5.79 31.75 38.4 33.5
a Camptothecin has been used as positive control (IC50 (µM) = 0.018 ± 0.008 on HMEC-1). b Data are expressed as
mean ± SD of three different experiments performed in duplicate. c Data are the mean of two different experiments
in duplicate. d SI = IC50 HMEC-1/IC50 P. falciparum strain.
2.3. In vitro Activity on Leishmania Parasites
To assess the antileishmanial activity of compounds 1–3 we tested them against promastigote
stage of L. infantum and L. tropica responsible for visceral and cutaneous leishmaniasis, respectively.
The results of this study are reported in Table 4 as IC50 values with the relevant selectivity indexes
(SIs). Considering the couple avarone/avarol, we can notice that, as observed for the antiplasmodial
effects, the reduced form (3) is substantially more potent than the oxidized form 1 on both investigated
Leishmania parasites. This has been reported also for several antileishmanial naphthohydroquinones
which resulted more active than the corresponding naphthoquinones [43]. Instead, the hydroquinone
metabolite 3 and the thiazinoquinone 2 exhibited similar values of IC50 in the range of low micromolar;
however, avarol (3) showed a significantly higher SI (see Table 4). Definitely, the above results displayed
that introduction of the 1,1-dioxo-1,4-thiazine ring in the structure of avarone (1) to give thiazoavarone
(2) meaningfully improves the antileishmanial activity, once again according to the antiplasmodial
effects (see Tables 2 and 4).
In addition, compounds 1–3 were also investigated against intracellular amastigotes, the clinically
relevant form of Leishmania. All compounds resulted from 2 to 4-fold more active against amastigotes
than promastigotes; the hydroquinone avarol 3 confirmed itself as a promising agent to be further
investigated in efficacy and selectivity, presenting the lowest IC50 value in the series and a SI greater
than 10 (Table 4) [44].
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Table 4. Activity of compounds 1–3 against promastigote stage of L. infantum and L. tropica and against
amastigote stage of L. infantum.
Compounds L. infantumIC50 (µM) a
SIp c
L. tropica
IC50 (µM) a
SIp c
L. infantum
Amastigotes IC50 (µM) b
SIa d
Avarone (1) 28.21 ± 0.32 2.2 20.28 ± 3.56 3.1 7.64 8.1
Thiazoavarone (2) 8.78 ± 0.26 0.38 9.52 ± 0.32 0.35 4.99 0.67
Avarol (3) 7.42 ± 0.27 5.0 7.08 ± 1.91 5.2 3.19 11.6
Amphotericin B 0.20 ± 0.03 0.17 ± 0.04 0.189
a Data are expressed as mean ± SD of three different experiments performed in duplicate. b Data are the mean of
two different experiments in triplicate. c SIp = IC50 HMEC-1/IC50 L. infantum (L. tropica) promastigotes. d SIa = IC50
HMEC-1/IC50 L. infantum amastigotes.
2.4. In Vitro Activity on S. mansoni
Compounds 1–3 were tested against larval stage (schistosomula), adult worm couples and eggs of
the platyhelminth S. mansoni. The most potent compound on schistosomula was thiazoavarone (2)
with a LC50 value in the low micromolar range (Table 5). The natural compounds (1 and 3) showed
comparable activity, with avarol (3) slightly more active than avarone (1), both showing a LC50 in the
high micromolar range (Table 5). Therefore, the presence of a thiazine ring was proved to be very
important for activity on schistosomula.
Table 5. Activity of compounds 1–3 against S. mansoni schistosomula.
Compounds LC50 (µM) a
Avarone (1) 42.77 ± 1.90
Thiazoavarone (2) 5.90 ± 2.59
Avarol (3) 33.97± 5.52
a Data are expressed as mean ± SD of three different experiments.
All three compounds 1–3 were also very active on adult worm pairs at 50 µM leading to parasites
death 7 days after treatment (Figure 4). However, when used at lower concentration (20 µM), only
avarol (3) strongly impaired parasites viability (only 20% survival), while thiazoavarone (2) was poorly
effective against the adult stage (Figure 4), despite its strong lethal effect on the larval stage (Table 5).
These results suggest the possibility that the double lipid bilayer coating the adult worms, namely the
tegument [45], can interfere with compound 2 uptake by adult parasites.
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In the process of drug discovery for schistoso iasis, strategy involving any i pair ent in egg
production and/or develop ent ust also be taken into account. In fact, upon ating with ales,
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hundreds of eggs each day. The eggs secreted in stool or trapped in the liver respectively cause disease
transmission and, as a result of inflammatory granulomas reactions, intestinal and hepato-splenic
diseases [46]. Therefore, compounds 1–3 were also assayed against the in vitro laid eggs (IVLEs).
The IVLEs produced in the first 48 h by S. mansoni pairs and treated for 3 days with vehicle or
compounds 1–3 were classified by microscopic observation according to the Vogel and Prata staging
system of egg maturation [47]. The thiazoavarone (2) resulted the most effective compound, impairing
eggs maturation already at 5 µM and resulting in undeveloped and severely damaged eggs at 20 µM
(Figure 5). Similar results were obtained with compounds 1 and 3 at 50 µM.
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2.5. Computational Studies and DFT Calculations
To rationalize the observed SARs, the steric and electronic features of compounds 1–3
were investigated by means of computational studies, including conformational analysis and
DFT calculations.
A systematic conformational search considering all rotatable bonds was applied to generate all
possible conformations of the compounds, which were, then, subjected to molecular mechanic (MM)
geometry optimization using the CFF force field and a distance dependent dielectric constant value
of 80 (Discovery Studio 2017, BIOVIA, San Diego USA; see the experimental Section for details) [48].
The global minimum energy conformer (GM) was identified for each compound. All the generated
conformers presented an energy difference from the GM (∆EGM) ≤ 3 kcal/mol. MM conformers
were, then, subjected to density functional theory (DFT) calculations. In order to mimic an aqueous
environment, all DFT calculations were performed using the conductor-like polarizable continuum
model (C-PCM) as solvent model [49]. Moreover, to characterize every structure as minimum, a
vibrational analysis was carried out (see the experimental Section for details). Fully optimized DFT
conformers were classified into families according to the values of their torsion angles (Tables 6 and 7
and Table S1).
Results evidenced that compounds 1–3 present common conformational features, characterized
by the electronic attraction between the hydrogen atoms of the first methylene group of the alkyl
substituent and the nearby quinone oxygen, which limits the conformational freedom of R′ (Figure 6).
Accordingly, the torsional angle τ1 showed just two sets of possible values (~±100◦; Tables 6 and 7
and Table S1), and for each of them the rigid sesquiterpene ring could assume three orientations with
respect to the thiazinoquinone/quinone/quinol ring (τ2 = ~60◦, ~−60◦ and ~180◦; Tables 6 and 7 and
Table S1). This determined a total number of six conformers (named I–VI; Figure 6). In the case of
the thiazinoquinone derivative 2, due to the presence of the two opposite flips of the thiazinoquinone
ring (τflip ~ ±60◦), we obtained two specular sets of conformers with the same conformational energy
(i.e., conformational enantiomers; Figure S10), as previously reported for other thiazinoquinone
derivatives [13,14].
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Figure 6. Density functional theory DFT conformers of compounds 1–3 superimposed by the carbon
atoms of the quinone/hydroquinone ring. Carbon atoms are colored according to conformer classification
(I = green, II = magenta, III = pink, IV = light blue, V = orange, and VI = Yellow); heteroatoms are colored
by atom type (H = white, O = red, N = blue, S = orange). Hydrogens are omitted for sake of clarity,
with the exception of those of the first methylene group of the R′ substituent, whose intramolecular
distances from the nearby oxygen atom of the quinone are reported.
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Table 6. ∆EGM values (kcal/mol) and torsion angle values (degrees) of the DFT conformers of 2.
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Conformer a ∆EGM (kcal/mol) Torsion Angles (◦)
τ1 b τ2 c
II 0.00 100.38 60.20
I 0.50 −110.21 55.83
IV 1.04 110.37 −72.73
III 1.25 −102.31 179.90
V 2.03 87.13 158.72
VI 3.02 −84.08 −54.03
the conformational enantiomers with the value of τflip ~60◦ are reported. b τ1 torsion angle is defined by e, f,
g, and h atoms. c τ2 torsion angle is calculated considering f, g, h, and i atoms.
Table 7. ∆E values (kcal/mol) and torsion angle values (degrees) of the DFT conformers of 1.
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sion angle is defined by a, b, c, and d atoms. b τ2 torsion angle is calculated considering b, c, , and e atoms.
The fixed position of the methylene group combined with the presence of the rigid sesquiterpene
moiety, place in the putative semiquinone radical produced upon one electron reduction/oxidation
several hydrogen atoms at a distance (≤3 Å) suitable for an intramolecular radical shift from the oxygen
atom to a carbon atom of R′ (see below).
Then, starting from the DFT minima, the redox properties of 1–3 were calculated. At this aim, we
considered the two electrons/two protons quinone reduction pathway in a protic solvent (Scheme S1)
and all the species involved in the pathway (Q•−, QH•, QH−, QH2) were generated and DFT optimized
using as starting structures the energetically favored DFT minima I and II.
Two possible protonated semiquinone species may be formed, depending on which of the two
quinone oxygen atoms is reduced/oxidized at first. The location of the lowest unoccupied molecular
orbital (LUMO) in 1 and 2 and of the highest occupied molecular orbital (HOMO) in 3 indicated the
oxygen opposite to the alkyl chain as the most probable site to be reduced and the one close to the alkyl
chain as the most probable site to be oxidized, respectively (Figure 7). It is worthy to be mentioned
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that, regarding the most probable oxidation pathway of 3 to its quinone form, since the deprotonation
step is supposed to be the first event in protic solvents (Scheme S1), we calculated the pKa values of
the two hydroxyl groups, too. Results indicated the hydroxyl group nearby the alkyl substituent as
the first to lose the proton (Figure S11), further supporting the formation of the hydroquinone radical
reported in Figure 7.
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The standard redox potential (E◦) and the standard Gibbs free energy (∆G0r d, aq) of each
electron-transfer reaction (see Scheme S1) alongside with the standard Gibbs free energy required for
the protonation of the resulting reduced species (∆G0H+) of the redox couple 1, 3 and 2 were calculated
(for details see the experimental Section). To further evaluate the propensity of 1 and 2 to undergo
a one-electron reduction, the energy of the lowest unoccupied molecular orbital (ELUMO) was also
taken into account. Similarly, we calculated the ionization potential (IP; i.e., −EHOMO) of the radical
anion QH− as indicative of the tendency of the deprotonated species of 3 to undergo a one-electron
oxidation. Finally, e considered the energy of the single occupied olecular orbital (ES ) of the
radical species as indicative of the ability to delocalize the unpaired electron. The resulting data are
reported in Tables 8 and 9.
Table 8. DFT calculated para eters and standard redox potentials (E◦; Q/Q•−) of compounds 1–3.
Cmp. Conf.
ELUMO a ES a ESOMO a ∆G◦red, aq a E◦ b ∆G◦H+ a
(Q) ( •−) (QH•) (Q/Q•−) (Q/ •−) (Q•−/QH•)
1, 3 I −10.62 143.34 −106.45 −94.58 328.57 −279.60
1, 3 II −10.68 143.42 −106.60 −95.13 304 65 −279.87
2 I −17.76 148.69 −158.60 −95. 97.63 −272.91
2 II −17.83 148.72 −159.93 −95.66 281.68 −273.03
a kcal/ l. b .
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Table 9. DFT calculated parameters and standard redox potentials (E◦; QH•/QH−) of compounds 1–3.
Cmp. Conf.
∆G◦red,aq a E◦ b ∆G◦H+ a IP a EHOMO a
(QH•/QH−) (QH•/QH−) (QH−/QH2) (QH−) (QH2)
1, 3 I −91.67 −454.64 −295.41 61.09 −158.06
1, 3 II −89.95 −529.31 −296.77 60.83 −156.34
2 I −95.22 −300.60 −290.49 130.87 −158.18
2 II −95.24 −299.70 −289.55 130.94 −159.27
a kcal/mol. b mV.
A first consideration can be derived comparing the redox properties of the quinone-based
compounds 1 and 2. With respect to 1, 2 showed either a higher tendency to acquire one electron (lower
ELUMO and ∆G0(red, aq); higher E◦; Table 8) and a higher stability of the QH• radical (lower ESOMO;
Table 8). While the ESOMO values of the anion radical species showed little difference (ESOMO Q•−;
Table 8), on the contrary, the differences became evident after the protonation step (ESOMO QH•). These
results, on one hand confirm the key role played by the 1,1-dioxo-1,4-thiazine ring on the electron
affinity [11,13,14]; on the other hand, support the hypothesis that the compound activity is related to
the formation of the semiquinone radical species. Indeed, the thiazinoquinone derivative 2 resulted
overall more potent than the quinone derivative 1.
A second consideration is that, as evidenced in Figure 7 and Figure S12, all the calculated
semiquinone radicals showed a hydrogen atom of the first methylene group together with, at least,
another hydrogen atom of the rigid sesquiterpene ring, at a distance suitable for an intra-molecular
hydrogen radical shift to the semi- reduced/oxidized oxygen atom (≤3 Å) (Table S2). By consequence,
as above mentioned, the presence of the sesquiterpene moiety as alkyl substituent is expected to
promote the putative “through space” intramolecular hydrogen radical shift leading to the formation
of the toxic radical species. In line with this hypothesis, 2 resulted the most potent thiazinoquinone
developed by us against P. falciparum D10 and W2 strains as well as against stage V gametocytes.
In addition, 1, although lacking the 1,1-dioxo-1,4-thiazine ring of 2, resulted still active on P. falciparum
D10 and W2 strains as well as on schistosomula, contrarily to what previously observed by us for other
1,4-benzoquinone derivatives when compared to the corresponding thiazinoquinone analogues [13,14].
Finally, the hydroquinone 3 showed a higher propensity to be oxidized to the semiquinone radical
(i.e., lower E◦ and IP of the QH− anion) with respect to the corresponding reduced form of 2 (Table 9).
Thus, the absence of the 1,1-dioxo-1,4-thiazine ring favors the one-electron oxidation reaction of 3.
The hydroquinone 3 resulted more active than the corresponding quinone 1 against all considered
parasites, while presenting the highest selectivity index with respect to mammalian cells. Both
the oxidized and the reduced forms could produce the same putative toxic radical species upon a
one-electron transfer reaction. In this view, our results suggest the presence in the parasite cell of
a bioactivation reaction partner preferentially binding the hydroquinone (reduced) form (3) rather
than the quinone (oxidized) form (1). This putative bioactivation partner seems not to be present in
human cells.
To investigate the role played by molecular pharmacokinetics on the observed SARs, we calculated
the distribution coefficient values of 1–3 (clogD, Table S3) (ACD/Percepta 2017). According to Lipinski’s
rules for drug absorption [50] the thiazinoquinone 2 showed a better cLogD value for cell membrane
passive diffusion (cLogD ~ 4) with respect to 1 and 3 (cLogD > 5). However, in specific developmental
stages (i.e., Pf late gametocytes, promastigote of L. infantum and L. tropica, amastigote of L. infantum,
and adult worms of S. mansoni) 3 resulted more active than 2 (Tables 2, 4 and 5; Figures 4 and 5).
According to what previously reported by us [14], this peculiar activity profile could be due to
the significant morphological changes in the parasite during the above-mentioned developmental
stages [51–53], which are likely to impair compound ability to penetrate into the parasite by passive
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diffusion, while it could still penetrate by exploiting the large number of transport proteins expressed
on the parasite membrane.
Taken together, the results of our computational investigation indicate that a toxic semiquinone
radical species [11,13,14] which can be produced starting both from quinone- and hydroquinone-based
compounds could mediate the anti-parasitic effects of the tested compounds 1–3.
3. Materials and Methods
3.1. General Methods
Solvents: Carlo Erba (Pomezia, Rome, Italy). Commercial reagents: Sigma–Aldrich (Saint Louis,
MO, USA). TLC: Silica Gel 60 F254, plates 5 × 20, 0.25 mm, Merck (Kenilworth, NJ, USA). Anhydrous
solvents: Sigma-Aldrich-Merck. High-resolution ESI-MS analyses were performed on a Thermo LTQ
Orbitrap XL mass spectrometer (Thermo-Fisher, San Josè, CA, USA). The spectra were recorded by
infusion into the ESI (Thermo-Fisher, San Josè, CA, USA) source dissolving the sample in MeOH.
1H (500 MHz) and 13C (125 MHz) NMR spectra were recorded on an Agilent INOVA spectrometer
(Agilent Technology, Cernusco sul Naviglio, Italy) equipped with a 13C enhanced HCN Cold Probe;
chemical shifts were referenced to the residual solvent signal (CDCl3: δH = 7.26, δC = 77.0). For
an accurate measurement of the coupling constants, the one-dimensional 1H NMR spectra were
transformed at 64 K points (digital resolution: 0.09 Hz). Homonuclear (1H–1H) and heteronuclear
(1H–13C) connectivities were determined by COSY and HSQC experiments, respectively. Two and
three bond 1H-13C connectivities were determined by gradient 2D HMBC experiments optimized for a
2,3J of 8 Hz. 3JH–H values were extracted from 1D 1H NMR. High performance liquid chromatography
(HPLC) separations were achieved on a Shimadzu LC-10AT (Shimadzu, Milan, Italy) apparatus
equipped with a Knauer K-2301 (LabService Analytica s.r.l., Anzola dell’Emilia, Italy) refractive index.
3.2. Collection, Extraction and Isolation
Several fresh specimens of D. avara were collected along the coast of Narlidere, Bay of Izmir
(Turkey, 38◦24′45 N 27◦8′18 E), in summer of 2017 and immediately frozen and stored at −25 ◦C until
the use. The identification of fresh material was performed by Mr. Arturo Facente while a voucher
specimen is deposited at Mugla University, Turkey.
The freshly thawed sponge (21.9 g dry weight after extraction) was homogenized and treated
at room temperature with methanol (3 × 1 L) and, subsequently, with dichloromethane (3 × 1 L).
The combined extracts were concentrated in vacuo to give an aqueous suspension that was subsequently
extracted with BuOH. The butanol soluble material (5.4 g of a dark brown oil), obtained after evaporation
of the solvent, was chromatographed on a RP-18 silica gel flash column using a gradient elution
(water→methanol→chloroform). The fractions eluted with H2O/MeOH 2:8 (v/v) were chromatographed
by HPLC on an RP-18 column (Luna, 3 µm C-18, 150 × 3.00 mm), using MeOH/H2O 95:5 as the
eluent (flow 0.5 mL/min). This separation afforded 4.5 mg of pure avarol (3, tR = 5.4 min) and
26.8 mg of avarone (1, tR = 9.4 min), identified by comparison of its spectral properties with literature
values [21–23].
Avarone (1): yellow powder; [α]D25 = +2.6 (c 0.0014, CH3OH); 1H NMR (CDCl3) spectrum is
reported in Supplementary Materials (Figure S6); HRMS (ESI): m/z 313.2156 [M + H]+ (calcd. for
C21H29O2: 313.2162) (Figure S7).
Synthesis of thiazoavarone (2). 20.3 mg of avarone (1, 0.065 mmol) were dissolved in 12 mL of a
mixture of CH3CN/EtOH 1: 1 (v/v) and kept under stirring at room temperature; then, a solution of
hypotaurine (7 mg, 0.065 mmol) in 2 mL of water was added dropwise together with a catalytic amount
of salcomine added in portions. The mixture was stirred for 48 h at room temperature before removing
the most of ethanol in vacuo and pouring the residue into water. The orange/yellow mixture was
extracted with diethyl ether (60 mL × three times) and the organic phase was washed with brine, dried
over sodium sulfate, filtered, and solvent was removed by rotary evaporator. The resulting mixture
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was chromatographed by HPLC on an RP-18 column (Luna, 3 µm C-18, 150 × 3.00 mm) eluting with
MeOH/H2O 75:25 (tR = 31.6 min) and afforded the pure compound 2 (11 mg, 46%).
Thiazoavarone (2): orange powder; [α]D25 = +19.2 (c 0.0035, CDCl3); 1H and 13C NMR data are
reported in Table 1. 1D and 2D NMR data, Figures S2–S5; HRMS (ESI): m/z 440.1865 [M + Na]+ (calcd.
for C23H31NO4SNa: 440.1866) (Figure S1).
Avarol (3): yellow powder; [α]D25 = +12.4 (c 0.0018, CH3OH); 1H NMR (CDCl3) spectrum is
reported in Supplementary Materials (Figure S8); HRMS (ESI): m/z 315.2337 [M + H]+ (calcd. for
C21H31O2: 315.2319) (Figure S9).
3.3. P. falciparum Cultures and Drug Susceptibility Assay
P. falciparum cultures were carried out according to Trager and Jensen with slight modifications [13].
The CQ-sensitive strain D10 and the CQ-resistant strain W2 were maintained at 5% hematocrit (human
type A-positive red blood cells) in RPMI 1640 (EuroClone, Celbio) medium with the addition of 1%
AlbuMax (Invitrogen, Milan, Italy), 0.01% hypoxanthine, 20 mM Hepes, and 2 mM glutamine at 37 ◦C
in a standard gas mixture (1% O2, 5% CO2, and 94% N2). All compounds were dissolved in DMSO
and then diluted with medium to achieve the required concentrations (final DMSO concentration <1%,
non-toxic to the parasite). Drugs were placed in 96-well flat-bottomed microplates and serial dilutions
made. Asynchronous cultures with parasitaemia of 1%–1.5% and 1% final hematocrit were aliquoted
into the plates and incubated for 72 h at 37 ◦C. Parasite growth was determined spectrophotometrically
(OD650) by measuring the activity of the parasite lactate dehydrogenase (pLDH), according to a
modified version of the method of Makler in control and drug-treated cultures [13]. The antiplasmodial
activity is expressed as 50% inhibitory concentrations (IC50); each IC50 value is the mean ± standard
deviation of at least three separate experiments performed in duplicate.
3.4. Gametocytes Cultivation and Susceptibility Assay
The transgenic P. falciparum 3D7 strain 3D7elo1-pfs16-CBG99 expressing the Pyrophorus
plagiophthalamusCBG99 luciferase under a gametocyte specific promoter was used in all the experiments.
Parasites were cultured and gametocytes obtained as previously described [54]. Late-stage gametocytes
were exposed to compounds at day 11 after N-acetylglucosamine (NAG) addition. Gametocytes stages
were counted in Giemsa stained smears and the percentage of stage V gametocytes was higher than
80%. Compounds were prepared by serial dilution, in 96-well plate, in complete medium. Plates were
incubated for 72 h at 37 ◦C under 1% O2, 5% CO2, 94% N2 atmosphere. Luciferase activity was taken
as measure of gametocytes viability, as previously described [55]. Briefly, drug-treated gametocyte
samples at 2% haematocrit were transferred to 96-well black microplates and d-luciferin (1 mM in
citrate buffer 0.1 M, pH 5.5) was added at a 1:1 volume ratio. Luminescence measurements were
performed after 10 min with 500 ms integration time using a Sinergy 4 (Biotek) microplate reader.
The IC50 was extrapolated from the non-linear regression analysis of the concentration–response curve.
3.5. In Vitro Promastigote Susceptibility Assays
Promastigote stage ofL. infantum strain MHOM/TN/80/IPT1 andL. tropica (MHOM/IT/2012/ISS3130)
were cultured in Schneider’s Drosophila medium (Lonza) supplemented with 10% heat-inactivated
fetal calf serum (HyClone) at 24 ◦C.
The complete medium used for antileishmanial activity assay was RPMI (EuroClone)
supplemented with 10% heat-inactivated fetal calf serum (EuroClone), 20 mM Hepes,
and 2 mM l-glutamine. To estimate the 50% inhibitory concentration (IC50), the MTT
(3-[4.5-dimethylthiazol-2-yl]-2.5-diphenyltetrazolium bromide) method was used. Compounds were
dissolved in DMSO and then diluted with medium to achieve the required concentrations. Drugs
were placed in 96-well round-bottom microplates and seven serial dilutions made. Amphotericin
B was used as the reference anti-leishmanial drug. Parasites were diluted in complete medium to
5 × 106 parasites/mL and 100 µL of the suspension was seeded into the plates, incubated at 24 ◦C for
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72 h and then 20 µL of MTT solution (5 mg/mL) was added into each well for 3 h. The plates were
then centrifuged, the supernatants discarded and the resulting pellets dissolved in 100 µL of lysing
buffer consisting of 20% (w/v) of a solution of SDS (Sigma), 40% of N,N-dimethylformamide (Merck)
in H2O. The absorbance was measured spectrophotometrically at a test wavelength of 550 nm and a
reference wavelength of 650 nm. The results are expressed as IC50 which is the dose of compound
necessary to inhibit parasite growth by 50%; each IC50 value is the mean ± standard deviation of
separate experiments performed in duplicate.
3.6. In Vitro Intracellular Amastigote Susceptibility Assays
THP-1 cells (human acute monocytic leukemia cell line) were maintained in RPMI supplemented
with 10% FBS (EuroClone), 50 µM 2-mercaptoethanol, 20 mM Hepes, 2 mM glutamine, at 37 ◦C in 5%
CO2. For Leishmania infections, THP-1 cells were plated at 5 × 105 cells/mL in 16-chamber Lab-Tek
culture slides (Nunc) and treated with 0.1 µM phorbol myristate acetate (PMA, Sigma) for 48 h to
achieve differentiation into macrophages. Cells were washed and infected with metacyclic L. infantum
promastigotes at a macrophage/promastigote ratio of 1/10 for 24 h. Cell monolayers were then washed
and incubated in the presence of test compounds for 72 h. Slides were fixed with methanol and stained
with Giemsa. The percentage of infected macrophages in treated and non-treated cells was determined
by light microscopy.
3.7. Cytotoxicity Assay
The long-term human microvascular endothelial cell line (HMEC-1) was maintained in MCDB
131 medium (Invitrogen, Milan, Italy) supplemented with 10% fetal calf serum (HyClone, Celbio,
Milan, Italy), 10 ng/mL of epidermal growth factor,1 µg/ml of hydrocortisone, 2 mM glutamine and
20 mM Hepes buffer (EuroClone). For the cytotoxicity assays, HMEC-1 were plated at 105 cells/mL
in 96-well flat bottom microplates. THP-1 cells were plated at 5 × 105 cells/mL in 96-well flat bottom
microplates and treated with 0.1 µM PMA for 48 h to achieve differentiation into macrophages. Cells
were then treated with serial dilutions of test compounds and cell proliferation evaluated using the MTT
assay described for promastigotes. The results are expressed as IC50, which is the dose of compound
necessary to inhibit cell growth by 50%.
3.8. In vitro Effects of Compounds on S. mansoni Parasites and Eggs
Schistosomula were prepared by mechanical transformation of cercariae, as previously
described [56]. The ATP-based viability assay with CellTiterGlo (Promega, Italy) on the larval
stage of schistosomes was carried out in 96-well, black, tissue culture plates by adaptation of a protocol
previously set up in our laboratory [56]. DMSO (vehicle) and gambogic acid (10 µM) were used as the
negative and positive controls in each plate and the percentage of viability for each compound was
calculated as the ATP reduction against vehicle (0%) and gambogic acid (100%).
All Animal work was approved by the National Research Council, Institute of Cell Biology and
Neurobiology animal welfare committee (OPBA) and by the competent authorities of the Italian
Ministry of Health, DGSAF, Rome (authorization no. 25/2014-PR and no. 336/2018-PR). All experiments
were conducted in respect to the 3R rules according to the ethical and safety rules and guidelines for
the use of animals in biomedical research provided by the relevant Italian law and European Union
Directive (Italian Legislative Decree 26/2014 and 2010/63/EU) and the International Guiding Principles
for Biomedical Research involving animals (Council for the International Organizations of Medical
Sciences, Geneva, Switzerland).
A Puerto Rican strain of S. mansoni was maintained by passage through albino Biomphalaria
glabrata, as the intermediate host, and ICR (CD-1) outbred female mice as previously described [56].
Female 4 to 7-week-old mice (Envigo, Udine, Italy) were infected with 200–400 double sex S. mansoni
cercariae by the tail immersion technique. Adult pairs were harvested from mice 7–8 weeks after
infection by reversed perfusion of the hepatic portal system and mesenteric veins. For the viability
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assays, 5 couples were incubated with the compounds in 3 mL DMEM complete tissue culture medium
containing 10% FBS for up to 7 days and phenotypic score was assigned as previously described [57].
For egg-treatment, 5 worm pairs were incubated for 48 h in 3 mL complete tissue culture medium;
next the parasites were removed and vehicle (DMSO) or compounds 1–3 were added to each plate
containing the eggs previously laid in vitro and observed for 72 h as previously reported [14]. Briefly,
images were recorded with a BX41 Olympus microscope and a bright field objective 10× served by a
SPOT RT 220-3 Diagnostic Instrument Inc camera. Egg maturation/morphological score was assigned
based on the Vogel and Prata’ staging system of egg maturation [47].
3.9. Molecular Modelling
Molecular modelling calculations were performed on E4 Server Twin 2×Dual Xeon-5520, equipped
with two nodes. Each node: 2× Intel® Xeon® QuadCore E5520-2.26Ghz, 36 GB RAM. The molecular
modelling graphics were carried out on a personal computer equipped with Intel(R) Core(TM) i7-4790
processor and SGI Octane 2 workstations.
Conformational property analysis. The apparent pKa and logD values (pH 7.4 and 7.2) of
compounds were calculated by using the ACD/Percepta software (ACD/Percepta, Advanced Chemistry
Development, Inc., Toronto, ON, Canada, 2017, http://www.acdlabs.com).
The compounds were considered neutral in all calculations performed as a consequence of the
estimation of percentage of neutral/ionized forms computed at pH 7.4 (blood pH value) and pH 7.2
(cytoplasm pH value) using the Henderson–Hasselbalch equation. The compounds were built using
the Small Molecule tool of Discovery Studio 2017 (Dassault Systèmes BIOVIA, San Diego). Then,
the built compounds were subjected to molecular mechanic (MM) energy minimization (ε = 80 × r)
until the maximum RMS derivative was less than 0.001 kcal/Å, using Conjugate Gradient [58] as
minimization algorithm. Atomic potentials and charges were assigned using the CFF forcefield [48].
The conformers obtained for each compound were used as starting structure for the subsequent
systematic conformational analysis (Search Small Molecule Conformations; Discovery Studio 2017).
The conformational space of the compounds was sampled by systematically varying the rotatable
bonds sp3–sp3 and sp3–sp2 with an increment of 60◦. The RMSD cutoff for structure selection was set
to 0.01 Å. Finally, to ensure a wide variance of the input structures to be successively fully minimized,
an energy threshold value of 106 kcal/mol was used as selection criteria. The generated structures
were then subjected to MM energy minimization (CFF forcefield; ε = 80 × r) until the maximum RMS
derivative was less than 0.001 kcal/Å, using Conjugate Gradient as minimization algorithm. Finally,
the resulting conformers were ranked by their potential energy values (i.e., ∆E from the global energy
minimum (GM)).
All MM conformers within 5 kcal/mol from GM has been then subjected to DFT calculations.
The calculations were carried out using the Gaussian 09 package [59]. All structures were fully
optimized at the B3LYP/6-31+G (d,p) level using the conductor-like polarizable continuum model
(C-PCM) [49,60,61]. In order to characterize every structure as minimum and to calculate the Gibbs
free energy a vibrational analysis was carried out at the same level of theory using the keyword: freq.
The RMS force criterion was set to 3 × 10−4 a.u. Partial charges, molecular orbitals and spin density
have been calculated using the natural bond orbital (NBO) method [62]. The resulting conformers
were ranked by their potential energy values (i.e., ∆E from the global energy minimum (GM)) and
classified by their dihedral angle values).
Calculation of redox properties. An appropriate way for calculating the redox potential is by using a
thermodynamic cycle. Accordingly, the redox potentials for the compounds was calculated by using
the Born–Haber cycle (Scheme 2), which links the Gibbs free energy change of the one-electron transfer
reaction in the gas phase with that of the same reaction in aqueous solution [63,64].
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Scheme 2. Born–Haber cycle for a generic one-electron transfer reaction in vacuo and in
aqueous solution.
Accordingly, the Born–Haber thermodynamic cycle allows to include the desolvation/solvation
effects by calculating the Gibbs free energy values of the reaction in gas phase and in solution. According
to this approach, the standard Gibbs free energy of the electron transfer (∆G0red,aq), was calculated
taking into account the free energy change in the gas phase (∆G0gas) and the solvation free energies of
the oxidized (∆G0solv(X)) and reduced species
(
∆G0solv(X
•−)) as reported in the following equation:
∆G0red,aq = ∆G
0
gas +
(
∆G0solv(X
•−) − ∆G0solv(X)
)
(1)
Accordingly, we, firstly, calculated the Gibbs free energy in gas phase by using the following
equation:
∆G0gas = G
0
gas(X
•−) −G0gas(X) (2)
ti f t t ci s • l
∆G0solv(X) = G
0
aq(X) −G0gas(X) (3)
∆G0solv(X
−) = G0aq(X•−) −G0gas(X•−) (4)
The values obtained were used to calculate the standard Gibbs free energy of the overall reaction
(∆G0red,aq; kcal·mol−1) according to Equation (1). The X and X•− species correspond in our case to Q and
Q•−, respectively in the first electron transfer, and to QH• and QH− in the second electron transfer (see
Scheme S1).
Finally, the ∆G0red,aq, were used to calculate the standard reduction potential by the Nernst equation:
E0 = −
4G0red,aq
nF
(5)
r is the number of lectrons involved in the process (i.e., 1) and the Faraday constant
(23.06 kcal mol−1 V−1).
r cti potential given by the Equation (5) is an absolute value of the parameter and
has to be referred to the standard hydrogen electrode (SHE; redox potential of 4.43 V), to t i t
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aqueous solution (using the C-PCM method). According to the Koopmans’ theorem [65], the ionization
potential (IP) is given by the negative of the value of the energy of the HOMO.
4. Conclusions
We investigated the antiparasitic potential of the marine sesquiterpene avarone (1), its reduced
form avarol (3), and thiazoavarone (2), a novel semisynthetic thiazinoquinone analogue obtained
through a condensation reaction of 1 with hypotaurine, which resulted completely regioselective. Both
the natural metabolites 1 and 3, as well as the semisynthetic derivative 2 resulted active against D10 and
W2 strains and late stage gametocytes of P. falciparum, against larval and adult developmental stages,
and eggs of the platyhelminth S. mansoni, and also against promastigote and amastigote forms of L.
infantum and L. tropica. The observed differences in the magnitude of the effects of the three molecules
allowed us to draw some interesting conclusions, strongly supported by the results of the DFT analysis.
In particular, the thiazinoquinone 2 resulted as significantly more potent than the quinone derivative 1
against D10 and W2 strains of P. falciparum as well as on the larval stage of S. mansoni. On the other
hand, compound 1, although lacking the 1,1-dioxo-1,4-thiazine ring, resulted still active on P. falciparum
and on Schistosoma larval stage, contrarily to what previously observed for other 1,4-benzoquinone
derivatives when compared to the corresponding thiazinoquinone analogues [13,14]. The calculated
redox properties of 1 and 2 evidenced for 2 either a higher tendency to acquire one electron and a
higher stability of the QH• radical. Noteworthy, thiazoavarone 2 resulted the most potent antimalarial
thiazinoquinone developed by us.
The hydroquinone 3 resulted more active than the corresponding quinone 1 against all considered
parasites, with the highest selectivity index with respect to mammalian cells. This led to hypothesize
the presence in the studied parasites of a bioactivation reaction partner preferentially binding the
reduced form (3) rather than the oxidized form (1). This putative bioactivation partner seems not to be
present in human cells. Finally, comparison of the standard redox potential (E◦) and of the ionization
potential (IP) of the QH- anion of 3 with those of the corresponding reduced form of 2, indicated a
higher propensity of 3 to be oxidized to the semiquinone radical and, thus, that the absence of the
1,1-dioxo-1,4-thiazine ring favours the one-electron oxidation reaction of 3.
These results confirm the key role played by the 1,1-dioxo-1,4-thiazine ring on the electron
affinity [11,13,14] and, mainly, corroborate the hypothesis that the compound activity is related to
the formation of a toxic semiquinone radical species, which can be produced, upon a one-electron
transfer reaction, starting both from quinone- and hydroquinone-based compounds. In the case of the
antiplasmodial activity (on the erythrocytic stage of the parasite), our previous results indicated that the
bioactivation partner can be represented by free heme (generated during hemoglobin digestion) [11,13].
On the contrary, in the case of S. mansoni as well as Leishmania parasites, at this stage, we do not know
the bioactivation partner of the compounds. However, reactive oxygen species (ROS) generation was
found to be involved in the pro-apoptotic mechanism of some natural marine derived thiazinoquinones
against Jurkat cells [66]. Thus, it cannot be ruled out that the putative semiquinone radical species
reacts with oxygen molecules in cells, generating ROS and future studies will be devoted to clarifying
this issue. Moreover, the observed difference between the activity trend of 1–3 against the different
parasites and their developmental stage may be related to morphological and/or metabolic differences
in the targeted organism/stage. Thus, the selective toxicity against the different parasites and their
developmental stages can be addressed, taking advantage of the possible bioactivation reaction partners
to form the putative toxic radical (i.e., one-electron reduction or oxidation reaction).
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